COVID-19：富士フイルム､バイオ医薬CDMO投資：FUJIFILM Diosynth Biotech（動画）：
Fujifilm to invest 928 million USD to FUJIFILM Diosynth Biotech facility in Denmark：
富士胶片将投资9.28亿美元用于扩大其在丹麦的大型生物制剂生产设施
2020年6月9日
富士フイルム：
Diosynthと、原薬生産能力を倍増し、原薬/製剤/包装まで、ワンサイト・ワンストップで対応できる受託体制も確立します。
バイオ医薬品CDMO/FUJIFILM Diosynth Biotechnologies（FDB）のデンマーク拠点に、約1,000億円の大型設備投資を行います。
FUJIFILM Diosynth Biotechnologies：（FDB）
- 2022年から2023年、製造設備を順次稼働、
- デンマーク拠点で、バイオ医薬品/原薬生産能力を倍増、
- 原薬から製剤・包装まで製造受託が行える体制を構築します。
世界の3拠点：
- 富士フイルムFDB
- 米国（ノースカロライナ州・テキサス州）
- 英国（ビリンガム市）
デンマーク拠点：第4の拠点
2019年8月、原薬製造ラインを拡張し、既存の動物細胞培養タンクと同サイズのタンクを6基増設します。
デンマーク拠点は20,000リットル動物細胞培養タンクを12基保有し、バイオ医薬品業界でも数少ない大規模な原薬製造拠点となります。
新棟を建設し、大型製剤製造ラインを新設。
3,500万本/年の充填ができる最新鋭の全自動型製剤製造システムの採用により、大量受託を可能とします。
さらに、包装ラインには、薬液が充填されたシリンジ（注射器）を多品種のオートインジェクター*4へ組立可能な装置や汎用性の高い自動ラベル貼付・梱包設備などを導入し、幅広い顧客ニーズに応えていきます。
- 抗体医薬品や
- ホルモン製剤、
- 遺伝子治療薬、
- ワクチンなど
バイオ医薬品/生産プロセスを開発し、バイオCDMO事業/2021年度売上目標1,000億円を達成します。
富士フイルム [日本]
https://www.fujifilm.com/jp/ja/news/list/5049
Fujifilm to invest 928 million USD to expand its large scale biologics production facility in Denmark
- Doubling the drug substance production capacity
- Establishing end-to-end capabilities in one site, including drug substance manufacturing, fill/finish, assembly, labeling and packaging
TOKYO, June 9, 2020 —
FUJIFILM
will make a major capital investment of approximately 928 million USD) in the Denmark site of FUJIFILM Diosynth Biotechnologies,
a leading contract development and manufacturing organization (CDMO) for biologics and advanced therapies.
The capital investment
will double the Denmark site’s current drug substance manufacturing capacity, and will expand its capabilities to include fill/finish, and enhance its current assembly, labeling and packaging services.
FUJIFILM Diosynth Biotechnologies (Denmark)
will expand production lines for bulk drug substance with the addition of a further six mammalian cell bioreactors, bringing the total to 12 x 20,000-liter bioreactors by fall 2023,
making the Denmark facility one of the few major large-scale manufacturing facilities in the bio-CDMO industry.
The development
will also include the addition of the Denmark site’s first fill/finish production line (added by summer 2023),
featuring
a fully-automated, cutting-edge system capable of producing up to approximately 35 million units per annum to cater to large-scale production.
In spring 2022,
a new packaging line equipped with facilities to assemble multiple types of auto-injectors* as well as automatic labeling, will be added to meet a broad range of customer needs.
Since the acquisition of the Denmark site last year, the facility’s strong manufacturing track-record, coupled with FUJIFILM Diosynth Biotechnologies’ technologies enabling a stable supply of high-quality biopharmaceuticals,
has led to new orders not only from existing clients, but also new clients, contributing to our rapid business expansion
In August 2019,
Fujifilm invested approximately 890 million USD to acquire Biogen’s manufacturing subsidiary in Denmark, for its world-class cGMP capabilities and its experienced talent.
The advanced capabilities at the Denmark site has led to promising collaborations including
the recent announcement of future manufacturing capacity reservation by the COVID-19 Therapeutics Accelerator,
an initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to speed-up the response to the global pandemic.
Fujifilm aims to achieve
100 billion yen in sales in its bio-CDMO business ** by fiscal year ending March 2022,
exceed 200 billion yen in sales by fiscal year ending March 2026,
Fujifilm Global
https://www.fujifilm.com/news/n200610_01.html